Entscheidung

UPC_CoA_464/2024, UPC_CoA_457/2024, UPC_CoA_458/2024, UPC_CoA_530/2024, UPC_CoA_532/2024, UPC_CoA_533/2024, UPC_CoA_21/2025, UPC_CoA_27/2025

Appeal RoP220.1

Datum

25. November 2025

Sprache

DE

Kammer

Court of Appeal, Luxembourg

Registernr.

UPC_CoA_464/2024, UPC_CoA_457/2024, UPC_CoA_458/2024, UPC_CoA_530/2024, UPC_CoA_532/2024, UPC_CoA_533/2024, UPC_CoA_21/2025, UPC_CoA_27/2025

Aktenzeichen

UPC_CoA_464/2024, UPC_CoA_457/2024, UPC_CoA_458/2024, UPC_CoA_530/2024, UPC_CoA_532/2024, UPC_CoA_533/2024, UPC_CoA_21/2025, UPC_CoA_27/2025

Parteien

Meril Italy Srl (Appellant in 464/2024 and Respondent in 530/2024),Meril GmbH (Appellant in 457/2024 and 21/2025 and Respondent in 532/2024 and 27/2025),Meril Life Sciences Pvt Ltd. (Appellant in 458/2024 and 21/2025 and Respondent in 533/2024 and 27/2025),Edwards Lifesciences Corporation (Appellant in 530/2024, 532/2024, 533/2024 and 27/2025 and Respondent in 464/2024, 457/2024, 458/2024 and 21/2025)

Patente in der Entscheidung7
  • EP 3 646 825
  • EP 3 205 308
  • EP 2 731 552
  • WO 2013/012801
  • US 201161508456

Schlagwörter

9

Persönliche Notizen

Melden Sie sich an, um persönliche Notizen zu dieser Entscheidung hinzuzufügen.

Rechtliche HinweiseDatenschutzerklärungCookies

© 2026 UPC Casalonga